Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resista
about
New Antituberculosis Drugs: From Clinical Trial to Programmatic UseManagement of multidrug-resistant TB: novel treatments and their expansion to low resource settingsEmerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infectionsThe application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosisNext-generation antimicrobials: from chemical biology to first-in-class drugsCurrent trends and intricacies in the management of HIV-associated pulmonary tuberculosisSecond line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspectiveCurrent strategies to treat tuberculosisNew anti-tuberculosis drugs and regimens: 2015 updateA new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Tuberculosis therapy for 2016 and beyond.Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic ModelMetabolic Perspectives on PersistenceClinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis.Insights from the Structure of Mycobacterium tuberculosis Topoisomerase I with a Novel Protein FoldCrystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis.Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 System.Physiology, Biochemistry, and Applications of F420- and Fo-Dependent Redox Reactions.Drug-Resistant Tuberculosis: Challenges and Progress.Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosisPopulation-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis.High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.Nonclinical models for antituberculosis drug development: a landscape analysis.Antituberculosis drugs in children.A retrospective review comparing treatment outcomes of adjuvant lung resection for drug-resistant tuberculosis in patients with and without human immunodeficiency virus co-infection.Synthetic investigational new drugs for the treatment of tuberculosis.The paradigm shift to end tuberculosis. Are we ready to assume the changes?The potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis.Targeting bacterial topoisomerases: how to counter mechanisms of resistance.WHO strategies for the programmatic management of drug-resistant tuberculosis.Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
P2860
Q26741138-6C0FCA2D-E096-4461-8AF3-B0D3D11FF3D9Q26765394-2AFDDF23-DAE3-4A14-818B-889AA8671855Q26771997-3C424B17-0B01-4F2F-B711-F207C5D7E387Q26781386-C7EE0E64-DD36-4F94-AAD9-5B8C3EE20553Q26795478-A4B9B91D-1041-433B-9A22-345507FC41F5Q26799749-E02B78E9-6C3A-462F-889E-273DB666F8A0Q28069032-16865A89-6BCC-4A70-96C1-76DAEEEF5BEAQ28074085-30DA2527-9956-4DCC-B87E-E2423C971C82Q28075252-682B2765-863C-4722-A0F2-075CE8EA484DQ28596775-F8F1F78A-5373-4C2A-B664-0A496072E51DQ28602112-A4856205-09A3-485A-B9C4-F805B8416D88Q30248788-7691BE86-83D4-4659-A2CD-59181235EA8CQ30379233-646ADA48-9812-4FCA-9036-2A94BDEB1482Q30398195-81E8E4A5-11E2-4322-8DD7-EA6BB4817EBCQ33760793-90F7E822-576A-4066-8B99-79D7A3678E9DQ33810290-B65CF2ED-937C-41AB-ADF3-74BFD70A9CE8Q35915044-340CFF52-0B0B-4781-BD7E-2336B993098BQ36019139-04A4F864-3136-4D00-8ACF-BBDC740AEE73Q36094215-D0FEB9DD-D7A8-412C-A783-2F9112C7EB3BQ36115081-56F2DF9C-E918-446F-B177-A59130D23C67Q36195588-2AC752B3-013F-49CD-8CE6-9F0DF8B2A72FQ36386227-6F57DC60-1A0B-4EEA-B6A0-06226AE1CDB1Q36535308-EF681E43-C598-479B-A4E1-134BF821FF70Q36607637-72D86A19-BDBA-4B12-BF24-3A0E7538A5C1Q36834801-75CD11CF-968C-464D-BDE6-594BC47780D2Q36902459-85A24383-D989-49CE-B362-5DCE6FFD8FC6Q36924283-2400B018-AC95-4BE9-8C82-521CFA2DC91EQ37133281-5B27AA61-9874-4E22-B0EE-EF3EE7CD6E5EQ37270722-F2237492-1DFB-49E8-A367-685D30C638DBQ37358635-DBA8B7C5-1C15-494B-B475-3D09F5602B8FQ37507802-F9FD9FD7-76FF-40E5-A902-EE77296D0E20Q38502294-5F991F1D-2E81-4C9D-9B5A-3E6BC93CC372Q38533435-A486E651-DDB9-4C2D-9ACE-5D0DD17A67C8Q38542716-33418A6A-A4F5-4142-98C8-4DCFBD989A3BQ38635790-1AFA53D5-26B8-4668-876E-5164818B4D9DQ38676708-388C32DE-D5BF-4007-AC89-AAC6F877EF05Q38806183-852D8F08-D79B-4084-8551-FEB3BA8E235DQ38855273-12012CA9-AD3A-42BE-8B24-B77CD74AAB1AQ38856343-C5180CB0-3468-4798-88CC-64544713BF73Q38973113-E4E0371C-D1A4-4CDA-AC18-92CB86910430
P2860
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resista
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficiency and safety of the c ...... ug-susceptible or drug-resista
@en
type
label
Efficiency and safety of the c ...... ug-susceptible or drug-resista
@en
prefLabel
Efficiency and safety of the c ...... ug-susceptible or drug-resista
@en
P2093
P50
P1433
P1476
Efficiency and safety of the c ...... ug-susceptible or drug-resista
@en
P2093
Almari Conradie
Amour Venter
Andreas H Diacon
Carl M Mendel
Christo van Niekerk
Daniel Everitt
Divan A Burger
Florian von Groote-Bidlingmaier
Kathleen Eisenach
Liesl Page-Shipp
P304
P356
10.1016/S0140-6736(14)62002-X
P407
P577
2015-03-18T00:00:00Z